Key result
Kv channel blocker tetraethylammonium inhibits tumorigenic human mammary epithelial cell proliferation by ~50%.
p-value: p=<0.01
Kv1.3 may serve as a novel molecular target for breast cancer therapy and its stage-specific expression pattern may provide a potential diagnostic marker.
Hypothesis-generating for Kv1.3 blockade in breast cancer; clinical translation remains unproven.
Voltage-gated K(+) (Kv) channels are widely expressed in the plasma membranes of numerous cells such as epithelial cells. Recently, it has been demonstrated that Kv channels are associated with the proliferation of several types of cancer cells. Specifically, Kv1.3 seems to be involved in cancer cell proliferation and apoptosis. In the present study, we examined the expression of Kv1.3 in immortalized and tumorigenic human mammary epithelial cells. We also evaluated the expression level of Kv1.3 in each stage of breast cancer using mRNA isolated from breast cancer patients. In addition, treatment with tetraethylammonium, a Kv channel blocker, suppressed tumorigenic human mammary epithelial cell proliferation. Therefore, Kv1.3 may serve as a novel molecular target for breast cancer therapy while its stage-specific expression pattern may provide a potential diagnostic marker for breast cancer development.
No takes yet. Share an insight, caveat, or question.
Jang et al. (2009) studied Breast cancer. Tetraethylammonium (TEA) vs. Untreated control / Normal M13SV1 cells was evaluated on Cell proliferation (p=<0.01). Treatment with 10 mM tetraethylammonium, a Kv channel blocker, significantly inhibited the proliferation of tumorigenic human mammary epithelial cells by more than 50%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: